+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

Lobular Breast Cancer Alliance Invasive Lobular Carcinoma Research Challenge Grants

Lobular Breast Cancer Alliance

Description

The AACR-Lobular Breast Cancer Alliance Invasive Lobular Carcinoma Research Challenge Grants is a joint effort to stimulate and develop creative, paradigm-shifting ideas in invasive lobular carcinoma (ILC) that have the potential to advance knowledge of lobular breast cancer detection, diagnosis, pathology, treatment, recurrence prevention, or surveillance.

Applications are invited from researchers currently in the field as well as investigators with experience in other areas of cancer or biomedical research.

Each grant provides $50,000 over one year for expenses related to the research project. Grant funds may be used for direct and indirect research expenses attributable to the project, which may include supplemental salary support, equipment, research/laboratory supplies, and other research expenses.

AI Based Application Success Predictor

1. Direct focus on invasive lobular carcinoma (ILC) (highest predictor)

This is the single most important predictor.

Competitive proposals must focus specifically on invasive lobular carcinoma, rather than breast cancer in general.

High-priority topics include:

ILC biology
ILC diagnosis
Imaging
Treatment
Metastatic ILC
Dormancy and recurrence
Rare ILC subtypes
Long-term follow-up

LBCA was established because ILC is biologically distinct from other estrogen receptor–positive breast cancers and has historically been underrepresented in research.

2. Alignment with LBCA's published ILC research priorities (very high predictor)

LBCA has identified several priority areas for funding:

ILC-specific clinical trials
Improved imaging and screening
Better surveillance for recurrence
Understanding ILC biology and metastasis
Development of targeted therapies
Creation of ILC-specific laboratory models
Development of tumor banks and registries
Integration of ILC into larger breast cancer studies

Applications addressing one or more of these priorities have particularly strong strategic alignment.

3. Innovation and paradigm-shifting science (very high predictor)

LBCA's partnered grant programs explicitly seek creative, paradigm-shifting ideas.

Competitive proposals often include:

Novel biological mechanisms
Innovative therapeutic strategies
New imaging technologies
AI-assisted diagnostics
Biomarker discovery
Precision medicine
New laboratory models
Computational approaches

Projects that simply extend existing breast cancer paradigms without addressing the unique biology of ILC are generally less competitive.

4. Potential to improve diagnosis, treatment, or recurrence prevention (very high predictor)

Strong proposals should clearly demonstrate potential to improve:

Early detection
Diagnostic accuracy
Disease staging
Treatment selection
Prevention of recurrence
Surveillance
Long-term outcomes

LBCA's mission is centered on improving the diagnosis, treatment, and follow-up care of people living with ILC.

5. Strong biological rationale and ILC-specific science (very high predictor)

Because ILC differs biologically from ductal breast cancer, reviewers expect proposals to explain why the research is specific to ILC.

Strong projects often investigate:

E-cadherin loss
Lobular tumor biology
Mechanisms of metastasis
Hormone signaling
Tumor microenvironment
Dormancy
Molecular targets unique to ILC

The scientific rationale should clearly justify why the work cannot simply be generalized from other breast cancer subtypes.

6. Strong translational and clinical potential (high predictor)

LBCA supports:

Basic science
Translational research
Clinical research
Clinical trials

Competitive applications should explain how discoveries could ultimately benefit patients through:

New therapies
Improved imaging
Better biomarkers
Personalized treatment
Improved surveillance
Clinical implementation

Translational pathways strengthen both laboratory and clinical proposals.

7. Inclusion of patient advocates (very high and distinctive predictor)

This is one of LBCA's most distinctive requirements.

LBCA requires grant applicants to:

Include patient advocates during proposal development
Obtain at least one patient advocate letter of support
Continue patient advocate involvement during funded research

Patient advocates are also involved in grant review.

Applications demonstrating meaningful patient engagement—not merely nominal participation—are particularly well aligned with LBCA's philosophy.

8. Strong investigator commitment to ILC research (high predictor)

For some partnered programs, investigators who are new to the ILC field must demonstrate a commitment to continuing dedicated ILC research beyond the proposed project.

Competitive investigators typically demonstrate:

Relevant expertise
Publications
Preliminary work
Long-term commitment to ILC
Ability to build an independent ILC research program

This helps ensure sustained growth of the relatively small ILC research community.

9. Rigorous methodology and preliminary evidence (high predictor)

Strong applications generally include:

Clear hypotheses
Appropriate study design
Robust methodology
Statistical rigor
Feasible milestones
Preliminary data (particularly for larger clinical grants)

For example, the LBCA–Shannon Klingman Clinical Research Grants expect studies to be based on preliminary data from ILC models or patients.

10. Potential to expand the ILC research ecosystem (high predictor)

LBCA's strategic plan emphasizes building long-term infrastructure for ILC research.

Projects that contribute to:

New registries
Biobanks
Collaborative networks
Clinical trial participation
Open dissemination
New laboratory models
Research partnerships

may have broader strategic value because they strengthen the overall ILC research community.

Specialties

Cancer

Oncology

Gynecology

Eligibility Requirements

At the start of the grant term (January 1, 2027), applicants must:

Have a doctoral degree (PhD, MD, MD/PhD, or equivalent) in a related field.
Be independent investigators.
- If eligibility is based on a future position, the position must be confirmed at the time of submission and CANNOT be contingent upon receiving this grant. Applicants are advised to contact the AACR’s Research and Grants Administration (RGA) at grants@aacr.org before submission to confirm they will hold an eligible position.
Work at an academic, medical, or research institution anywhere in the world

At the start of the grant term (January 1, 2027), applicants cannot:

Be a candidate for a further doctoral degree.
Be an employee or subcontractor of a U.S. federal government entity or for-profit private industry. They may serve as collaborators, but no grant funds may be directed toward these individuals.
Concurrently hold another AACR grant.
- Current AACR grantees may apply only if their current grant ends before the start of the grant term for this funding opportunity (i.e., January 1, 2027). Also, the terms of their current grant must stipulate that the final progress reports be approved by the AACR before January 1, 2027.

All applicants with questions about eligibility should contact the AACR’s Research and Grants Administration at grants@aacr.org before submitting an application.

Sponsor Details

Sponsor Institute/Organizations: Lobular Breast Cancer Alliance

Sponsor Type: Corporate/Non-Profit

Address: 615 Chestnut St., 17th Floor Philadelphia, PA 19106-4404

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity